ABT Stock: BTIG Trims Price Target but Holds Buy Rating as Abbott Trades Near 52-Week Low
By TrendSpider Editor
BTIG analyst Marie Thibault reaffirmed a Buy rating on Abbott Laboratories but cut her price target from $140 to $131, a move that arrives as ABT shares trade at $101.67, just cents above the stock's 52-week low of $101.82. The price target reduction signals some recalibration in near-term expectati
ABT Stock: BTIG Trims Price Target but Holds Buy Rating as Abbott Trades Near 52-Week Low
BTIG analyst Marie Thibault reaffirmed a Buy rating on Abbott Laboratories but cut her price target from $140 to $131, a move that arrives as ABT shares trade at $101.67, just cents above the stock's 52-week low of $101.82. The price target reduction signals some recalibration in near-term expectations even as the firm maintains a constructive long-term stance on the medical device and diagnostics giant. With the 52-week high sitting at $139.05, Abbott shares have shed significant ground over the past year, making this confirmation of conviction notable against a backdrop of persistent selling pressure.
Key Drivers of the ABT Stock Move
- Main Catalyst: BTIG's Marie Thibault confirmed a Buy rating on ABT while reducing the price target by $9, moving it from $140 down to $131. The action reflects a trim in valuation assumptions but a continued belief in the upside thesis for Abbott shares.
- Bull Case: Even after the cut, the new price target of $131 represents more than 28% upside from the current price of $101.67. A Buy confirmation from a covering analyst at these depressed levels could attract attention from value-oriented investors looking for a re-entry point near the 52-week low.
- Bear Case: The fact that BTIG felt compelled to lower the price target from $140 to $131 suggests that fundamental or macro headwinds are weighing on near-term estimates. ABT is trading below both the prior and revised price targets by a wide margin, and the stock's proximity to its 52-week low of $101.82 indicates the market has not yet found a floor despite analyst support.
The forward setup for Abbott is complicated by the stock's technical position. Trading at $101.67 with only $0.15 of cushion above the 52-week low of $101.82, a break of that level could invite additional technical selling. The average price target of $131 implies the Street sees meaningful recovery potential, but the gap between analyst targets and the current price reflects uncertainty rather than confidence in a near-term catalyst. The BTIG price target reduction to $131, which still sits far above the current quote, suggests analysts are maintaining faith in Abbott's longer-term fundamentals while acknowledging that the path higher may take longer than previously anticipated. Investors will be watching closely for any update on Abbott's core diagnostics and medical device segments that could serve as a re-rating event.
ABT Analyst Ratings and Price Targets
BTIG analyst Marie Thibault took action on Abbott Laboratories on March 31, 2026, confirming a Buy rating while trimming the price target to $131 from a prior target of $140. The $9 reduction in the price target is the headline adjustment, though the maintained Buy designation keeps ABT in the firm's favored column. The consensus average price target across covering analysts stands at $131, aligning directly with BTIG's revised figure. With ABT currently at $101.67, the average price target implies upside of approximately 29% from current levels, a spread that reflects either significant undervaluation or a Street that has been slow to adjust targets lower as the stock has declined toward its annual low.
ABT Seasonality
March and early April have historically represented a transitional period for large-cap healthcare names, as investors reposition ahead of first-quarter earnings season. For Abbott specifically, the end of the first quarter often draws attention to diagnostic testing volumes and device procedure trends, both of which can serve as early signals for how the company's results may shape up when it reports.
ABT Relative Performance
ABT is down 0.21% on the session as of March 31, 2026, a modest daily decline that nonetheless keeps the stock pinned near its 52-week low of $101.82. The stock's position at the low end of its 52-week range of $101.82 to $139.05 stands in contrast to the broader healthcare sector, which has shown more resilience in recent months. The wide gap between the current price and the 52-week high underscores that Abbott has been a notable underperformer relative to where it traded less than a year ago.